Here, we provide a rationale for routine testing of SSTR2 status in NPC patients for prognostic purposes, for exploration of the value of 68Ga-DOTA-peptide PET-CT imaging for NPC diagnosis and surveillance and for offering a theragnostic treatment for advanced and recurrent NPC. This evidence concerns the gene SSTR2 and nasopharyngeal carcinoma.